Daniel Bonner
Co-founder, Sr VP of Platform @Seaport Therapeutics
Cambridge, MA, US
EMAILS
MOBILE NUMBERS
+91 *********19
Signup · Get unlimited contacts
WORK HISTORY
Apr 2024 — Present
Co-founder, Sr VP of Platform @Seaport Therapeutics
View department →
EDUCATION
2002 — 2006
Cornell University
B.S., Materials Science and Engineering
2006 — 2011
Massachusetts Institute of Technology
Ph.D., Biomedical/Medical Engineering
ABOUT DANIEL BONNER
Leading Seaport’s Glyph™ lymphatic-targeting prodrug platform from technology in-licensing through clinical validation, establishing human proof of concept for the platform and resulting in multiple therapeutic candidates including GlyphAllo™ (SPT-300) and GlyphAgo™ (SPT-320).
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.